ribociclib,fulvestrant
novartis
['fulv', 'ribociclib', 'maintain trial', 'breast']
a randomized, phase ii trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cdk 4/6 in patients with unresectable or hr+, her2-negative metastatic breast cancer: maintain trial #asco22 
Medicina Interna - Oncología Clínica - Profesor Titular @UPBColombia - Clínica Astorga. #Medellín / #Colombia mlujanonco@gmail.com #OncTwitter #Metaanalysis